Next Article in Journal
Crop Rotation and Minimal Tillage Selectively Affect Maize Growth Promotion under Late Wilt Disease Stress
Next Article in Special Issue
Isavuconazole for COVID-19-Associated Invasive Mold Infections
Previous Article in Journal
Understanding the Dynamics of Blast Resistance in Rice-Magnaporthe oryzae Interactions
Previous Article in Special Issue
Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant Candida parapsilosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 8
Issue 6
10.3390/jof8060585
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Concurrent Infection with SARS-CoV-2 and Pneumocystis jirovecii in Immunocompromised and Immunocompetent Individuals

by
Francesca Gioia
,
Hanan Albasata
and
Seyed M. Hosseini-Moghaddam
*
Transplant Infectious Diseases Program, Ajmera Transplant Centre, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2N2, Canada
*
Author to whom correspondence should be addressed.
J. Fungi 2022, 8(6), 585; https://doi.org/10.3390/jof8060585
Submission received: 19 March 2022 / Revised: 24 May 2022 / Accepted: 24 May 2022 / Published: 30 May 2022
(This article belongs to the Special Issue Fungal Infections and COVID-19)
Review Reports Versions Notes

Abstract

:
Coronavirus disease 2019 (COVID-19) may occur with concurrent infections caused by bacterial and fungal microorganisms. This systematic review evaluated studies reporting concomitant COVID-19 and Pneumocystis jirovecii pneumonia (PJP). We found 39 patients (74% male, median age: 56.8 (range: 11–83) years), including 66% immunosuppressed individuals (23% HIV-infected and 41% on long-term corticosteroid therapy). Patients were characteristically severely ill (mechanical ventilation: 70%), associated with 41% mortality. The median lymphocyte count was 527 cells/mm3 (range: 110–2200), and the median CD4+ T cell count was 206 cells/mm3 (range: 8–1021). We identified three patterns of concurrent COVID-19 and P. jirovecii infection. The first pattern (airway colonization with a low burden of P. jirovecii) does not seem to modify the COVID-19 course of illness. However, P. jirovecii superinfection, typically occurring weeks after COVID-19 diagnosis as a biphasic illness, and P. jirovecii coinfection characteristically results in progressive multilobar pneumonia, which is associated with poor outcomes. To support this categorization, we reported three patients with concurrent PJP and COVID-19 identified in our institution, presenting these clinical scenarios. The diagnosis of PJP requires a high index of suspicion, since clinical and radiological characteristics overlap with COVID-19. Observational studies are necessary to determine the PJP burden in patients with COVID-19 requiring hospitalization.

1. Introduction

P. jirovecii is a common microorganism that can be detected from respiratory specimens of asymptomatic healthy adults and children [1,2]. The prevalence of P. jirovecii in the general population is not well established. Several studies in different regions of the world have reported a colonization rate from 0% to 65%, depending on the sample and the laboratory technique used for the detection of P. jirovecii and also on the population studied [3,4,5]. Data from Chile showed P.jirovecii in 61% of autopsy specimens in healthy adults who died in the community of violent causes [6].
Asymptomatic acquisition of P. jirovecii probably occurs in childhood. Various studies showed the presence of antibodies against P. jirovecii in children [7,8]. Vargas et al. described seroconversion in 85% of healthy children aged between 2 and 20 months, and a P. jirovecii DNA was identified in nasopharyngeal aspirates of 32% of infants until 2 years of age during episodes of mild respiratory infection [9]. According to a study conducted in Spain, P. jirovecii seroprevalence increased with age, reaching 52% at age 6, 66% at age 10, and 80% at age 13 [10]. Hence, the prevalence of infection with P. jirovecii appears to increase with age.
In immunocompromised hosts, P. jirovecii can cause Pneumocystis jirovecii pneumonia. A growing number of studies have shown evidence of PJP in HIV-negative immunocompromised patients [11]. The most recognized risk factors for developing PJP in non-HIV patients included immunosuppressive therapy, such as glucocorticoid use, and CD4+ lymphocytopenia [12].
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may cause a progressive coronavirus disease 2019 (COVID-19). A wide spectrum of the immune response to SARS-CoV-2 is expected, ranging from a severe systemic inflammation to a marked systemic immune suppression (i.e., immunoparalysis) [13]. Recent studies showed that profound depletion of CD4+ lymphocytes and NK cells is common in patients with severe COVID-19 [14]. Immunosuppressive therapy and treatment with glucocorticoids that are routinely considered for the management of severe COIVD-19 cause further immune suppression and have the potential to promote the development of opportunistic infection.
From the beginning of the pandemic, several studies have shown that severely ill COVID-19 patients are predisposed to concurrent infections caused by different microorganisms [15,16]. COVID-19 likely increases the risk of invasive fungal infection (IFI). Treatment of patients with severe COVID-19 using systemic glucocorticoids and immunosuppressive agents [17,18] can increase the risk of IFIs [19,20,21,22]. Glucocorticoid therapy could be continued for 10 days or until discharge. In this population, the occurrence of IFIs also may be the result of a variety of factors, including epithelial barrier damage, admission to the intensive care unit (ICU), invasive mechanical ventilation (IMV), and prolonged hospitalization [23].
Some IFIs, such as invasive aspergillosis, systemic candidiasis, and mucormycosis, have been frequently reported in patients with severe COVID-19 [24,25,26,27,28]. Several patients with moderate-to-severe COVID-19 have been reported with P. jirovecii simultaneous infection, in which lymphopenia and corticosteroids appear to be the main PJP risk factors [29].
Furthermore, P. jirovecii simultaneous infection in COVID-19 patients represents a significant diagnostic challenge for several reasons [12]. The clinical presentation and radiological futures of the two diseases overlap [30], making it difficult to distinguish between them, especially in high-risk patients receiving glucocorticoid therapy [31]. In COVID-19 severely ill patients, the microbiological diagnosis of PJP could be a problem. The diagnosis of SARS-CoV-2 infection is routinely made on upper respiratory tract specimens, while the diagnosis of PJP requires sampling from lower airways. Thus, concomitant or superimposed PJP are likely underestimated in COVID-19 patients. The diagnostic tools for PJP and other IFIs are not well validated in upper respiratory specimens [32,33]. In addition, the current clinical diagnostic algorithm for PJP does not apply to COVID-19 patients, making it difficult to establish if the detection of P. jirovecii should be interpreted as real infection or colonization [29,30,31,32,33,34,35].
This narrative review aims to analyze the information available in the literature about COVID-19 and simultaneous infection with P. jirovecii, describing the diagnostic challenges, clinical characteristics, outcomes, and prognosis.

2. Materials and Methods

We performed a qualitative and comprehensive review of the literature using a combination of database-specific subject headings and text words for the main concepts of COVID-19 and P. jirovecii concomitant infection. The strategy was initially designed for Pubmed and then translated for Embase. We included studies published in the databases from 1 January 2022 to 19 April 2022.
We included case reports, case series, and observational studies, including hospitalized COVID-19 patients with P. jirovecii concomitant infection. Conference proceedings and books were removed. English, Italian, or Spanish studies were included. See Data S1 for full search strategies.
We only included studies with a confirmed diagnosis of COVID-19 using real-time polymerase chain reaction (RT-PCR) from a nasopharyngeal or oropharyngeal swab or BAL. The diagnosis of PJP was considered ‘proven’ if P. jirovecii was detected on BAL with immunofluorescence microscopy (IFM); ‘probable’ in the presence of host factors, clinical features, and microbiological evidence (PCR for P. jirovecii on respiratory samples or serum Beta-D-Glucan assay (BDG)); and ‘possible’ in the absence of microbiological evidence, according to the European Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSGERC) criteria [12].
Detailed information about the studies, demographics, and clinical characteristics were collected and are summarized in Table 1. The collected data included age, comorbidities, radiological findings, and absolute lymphocyte count during PJP diagnosis; lowest CD4+ T cell count; long-term corticosteroid exposure before admission; and other immunosuppressive medications or conditions.

Clinical Patterns of PJP

Considering the course of illness, clinical data, and radiographic findings, we defined coinfection as microbiologic evidence of infection with P. jirovecii during moderate-to-severe COVID-19 requiring anti-PJP therapy. Patients with COVID-19 who improved following treatment (e.g., glucocorticoid therapy) and subsequently developed microbiologically proven PJP (i.e., biphasic illness) were defined as a superinfection. We categorized patients with a low burden of P. jirovecii (e.g., <103 in quantitative PCR), which did not require treatment, as airway colonization. Using these definitions, we subsequently presented three patients with COVID-19 and a laboratory diagnosis of PJP.

3. Results

3.1. Literature Review

Demographic and Clinical Characteristic of Patients

Twenty case reports and two observational studies described 39 patients with concurrent P. jirovecii and SARS-CoV-2 infection (74% male, median (range) age: 56.8 (11–83)). A total of 66.6% (26/39) of patients were immunosuppressed at the baseline (e.g., HIV-infection, receiving immunosuppressive drugs). Among immunocompromised patients, 23% (9/39) were HIV-infected. Forty-one percent (16/39) of patients received long-term corticosteroid therapy before being diagnosed with COVID-19. Other immunosuppressive therapies included leflunomide, tacrolimus, mycophenolate mofetil, fludarabine, cyclophosphamide, and rituximab.

3.2. Diagnosis and Outcome

PJP was diagnosed in 41% (16/39) of cases based on BAL specimens, in 7.6% (3/39) on tracheal aspirate specimens (TA), and 12.8% (5/39) on sputum samples. In two cases, histopathological or cytological findings were described. Among the 10 cases reported by Alaino et al. [34], no source of the low respiratory tract (LRT) sample was specified. A possible PJP diagnosis was established in four patients with no microbiological evidence.
PCR was the most common method for PJP diagnosis (66.6%), followed by microscopy staining and IFM (23%). Data for BDG were available for 17 patients (median: 260 ng/L). Aspergillus spp. coinfection was detected in 15.3% (6/39) patients.
All patients had radiographic findings compatible with PJP. The most common radiologic feature was ground-glass opacity (GGO), followed by lobar infiltration and pleural effusions.
The median lymphocyte count during PJP diagnosis was 527 cells/mm3 (range: 110–2200), and the median CD4+ T cell count was 206 cells/mm3 (range: 8–1021). Most patients were critically ill, and 70% (26/39) needed mechanical ventilation. PJP was treated in 76.9% of patients (30/39), most with sulfamethoxazole-trimethoprim (TMP-SMX) (28/39). In 2/39 cases, echinocandins were used. The mortality rate was 41% (16/39).

3.3. Brief Description of Three Cases in Our Institution

In our institution, we identified three cases of COVID-19 and simultaneous PJP diagnosis.

3.4. CASE 1 and 2: Superinfection with P. jirovecii

The first case was a 63-year-old male with a past medical history of chronic lymphocytic leukemia diagnosed in 2016 and who received treatment with obinutuzumab and venetoclax. He also had hypertension and ischemic heart disease. He had no prior history of steroid use. He received two doses of the COVID-19 vaccines in April and May 2021. He initially presented with a moderate cough associated with shortness of breath at the beginning of July 2021. He underwent BAL, and his SARS-CoV-2 test was reported positive. He did not receive any specific treatment for COVID-19. He was subsequently readmitted to our hospital at the end of July 2021 due to shortness of breath, anosmia, and ageusia. He was afebrile and normotensive. His oxygen saturation was 93% using 2 L/min O2 via a nasal cannula. The initial laboratory evaluation revealed leukocytosis and neutrophilia. The chest CT showed a worsening of ground glass opacity (GGO) in both upper lobes, with a reverse halo appearance, consolidation, and bibasal pleural effusion. He underwent the second BAL, and his P. jirovecii PCR test was positive (1123 copies/mL). SARS-CoV-2 was still detectable in the BAL-PCR test. He was treated with trimethoprim-sulfamethoxazole (TMP-SMX) associated with tapering doses of prednisone for 21 days and subsequently discharged home.
The second patient was a 43-year-old male with primary refractory acute myeloid leukemia, treated with intravenous cytarabine and oral hydroxyurea. He was also on 20 mg of dexamethasone from October 2021, receiving a tapering dose for more than four weeks. He did not receive SARS-CoV-2 vaccines. In December 2021, he developed mild respiratory symptoms, and his nasopharyngeal swab of SARS-CoV-2 was positive. At this time, he did not receive any specific treatment for COVID-19. He was admitted with fever (T: 38.8 °C), dyspnea, and chest pain one month later. His oxygen saturation was 95% while receiving 2 L/min O2 via a nasal cannula. His nasopharyngeal swab of SARS-CoV-2 was still positive. His laboratory evaluation revealed severe neutropenia and lymphopenia. The chest CT showed multilobular consolidation, pulmonary nodules, and GGO. Despite receiving glucocorticoid therapy and remdesivir for COVID-19 pneumonia, his symptoms and oxygen requirement did not improve. Three days after the admission, he underwent a bronchoscopy, which confirmed the diagnosis of PJP (PCR for P. jirovecii: 10,700 copies/mL). In addition, BAL was positive for COVID-19 (Omicron variant). Recovery began after treatment with TMP-SMX, and the patient was discharged home.

3.5. CASES 3-Coinfection with P. jirovecii

The third case was a 62-year-old male admitted in December 2020 for induction of acute lymphoblastic leukemia with blinatumomab and ponatinib.
He had a past medical history of hypertension and hepatitis B treated with entecavir. He had a prior history of steroid use (≥30 mg of prednisone daily) for more than 4 weeks. He did not receive a COVID-19 vaccination.
He presented with febrile neutropenia and hypoxia, requiring oxygen in a nasal cannula of 2 L/min. Laboratory evaluation revealed severe neutropenia and a normal lymphocyte count. His chest CT showed extensive consolidation in the right lower lobe. He underwent a bronchoscopy, and both SARS-CoV-2 PCR and P. jirovecii PCR (3250 copies/mL) were positive. The patient received a 21-day course of treatment with TMP-SMX associated with adjunctive glucocorticoid therapy. He was discharged home one month later.

4. Discussion

The present review showed that PJP could be at least a component of the causal complex of pneumonia in patients with severe COVID-19. Treatment regimens for the management of severe COVID-19 may cause an immunodeficiency state. Additionally, SARS-CoV-2 infection may cause dysregulation of immune system function. We identified 39 COVID-19 patients in the literature with simultaneous infection with P. jirovecii. Almost half of them had immunosuppressive conditions, including HIV-infection and long-term corticosteroid therapy, before PJP diagnosis. Lymphocytopenia was a common finding in almost all patients, and they frequently had CD4+ T cell counts less than 400 cells/mm3. The most common radiological feature described was GGO and diffuse bilateral infiltration. PJP was diagnosed by a specimen source of BAL primarily, and PCR was used in more than half of the LRT specimens. Most patients received anti-PJP therapy, predominantly TMP-SMX; however, the patients were severely ill, wih most requiring IMV, and the mortality rate was high. The overall mortality in reported cases was considerably high, indicating that PJP is associated with an unfavorable outcome in patients with COVID-19, and a timely diagnosis may be lifesaving.
Due to similarities in radiological and clinical findings among patients with COVID-19 and PJP, the differential diagnosis is challenging. COVID-19 and PJP may present overlapping clinical and radiological manifestations [31,55,56]. Patients present with similar features of dry cough, exertional dyspnea associated with O2 desaturation, and relatively normal chest auscultation [37,57]. The chest CT findings for both conditions are similar, with a GGO pattern and thickening of the interlobular septum [58,59]. The presence of pleural effusions, lung cysts, and pneumothorax should support a PJP diagnosis [60,61,62]. The gold standard for PJP diagnosis is based on microscopic visualization of P. jirovecii in LRT, especially BAL, due to its higher sensitivity [32,33]. On the other hand, COVID-19 diagnosis does not need bronchoscopy. Moreover, BAL is usually avoided in patients with COVID-19 due to the risk of O2 desaturation and SARS-CoV-2 aerosolization. All these factors undoubtedly cause underestimation of PJP incidence in COVID-19 patients. Therefore, it may be reasonable to include PJP in the differential diagnosis of patients with severe COVID-19 and a lack of improvement following glucocorticoid therapy.
Lymphocytopenia and a low CD4+ T cell count are common futures in patients with severe COVID-19, which correlate with the severity of illness [63,64]. Patients with a poor CD4+ T cell-count are susceptible to P. jirovecii colonization and PJP [12,65,66,67]. Many studies suggested that the immune dysregulation in patients with severe COVID-19, especially CD4+ lymphopenia, may increase the risk of PJP [30,35,68,69]. Patients with PJP and SARS-CoV-2 infection may have lymphopenia without any other classical PJP risk factors [35]. Some studies have cast doubt on the relationship between the lymphocytopenia encountered in severe COVID-19 and PJP, since lymphopenia in these patients may be transient. Blaize et al. performed 423 P. jirovecii PCR assays on respiratory samples obtained from 145 patients with severe SARS-CoV-2 infections; most of them (79%; 113/143) had a mild lymphocytopenia (1000 cells/mL), and almost all (99.3%; 420/423) had a negative P. jirovecii PCR test [54] However, this level of lymphopenia is not generally considered a PJP risk factor, and it would be of interest to have a comparable analysis using a more severe lymphopenia (<800 cells/mL). Further investigation is necessary to determine the risk of PJP in different levels of lymphopenia.
In addition to lymphopenia, COVID-19 also produces epithelial damage with resulting impaired mucociliary clearance, which may increase the susceptibility to PJP, as seen in other IFIs [26,70]. Recently, a study by Kottom et al. demonstrated the role of airway epithelial cells in binding and subsequently recognizing microorganisms, such as P. jirovecii, and in the initiation of the immune response [71].
Simultaneous infection with P. jirovecii has been shown with other respiratory viral pathogens. There is evidence that P. jirovecii is responsible for 7% of simultaneous infections among non-immunocompromised patients admitted to ICUs with influenza [72]. Single-center studies showed tha P. jirovecii might be detected in up to 9% of respiratory samples from patients with COVID-19 admitted to ICUs [34,54,73]. The noteworthy point is that there was no systematic approach to detect concomitant PJP in all those studies. The data were collected at the beginning of the pandemic when steroids and IL-6 inhibitor biologics were not widely used in patients with COVID-19. Currently, patients with severe COVID-19 routinely receive glucocorticoid therapy for 10 days or until hospital discharge, and a higher rate of infection with P. jirovecii is expected.
The present review identified almost three patterns of simultaneous infection with P. jirovecii (Table 2). The first pattern is more likely to be airway colonization with P. jirovecii. In the study of Alanio et al., 9 of 108 patients (9.3%) had a positive P. jirovecii PCR test, and more than a half (n = 6) did not receive any treatment [34]. Similarly, Blaize et al. described two patients with severe COVID-19 and a positive P. jirovecii PCR test from BAL specimens who improved without PJP treatment. Both patients had a low burden of microorganisms (<3 log). The serum BDG level was tested in one patient and was negative. None of these two patients presented with classical PJP host factors [54].
The second pattern of PJP is superinfection, occurring days or weeks after COVID-19 symptom onset as a biphasic illness. This presentation is well described by Gentile et al. [42]. All patients in this cohort developed PJP after clinical resolution of COVID-19 pneumonia, and the median time between COVID-19 symptoms and PJP diagnosis was 40 days. There were no pre-existing PJP risk factors in any of those patients except one, but all received at least 2 weeks of high-dose steroids, and the mean CD4+ T cell count at PJP diagnosis was 141 cell/mm3 (range: 77–953.5). Similarly, Gerber et al. [40] described four cases; two of them did not have any risk factor for PJP before the COVID-19 diagnosis, and developed PJP 25 and 40 days after admission for COVD-19. Both patients received glucocorticoid therapy for COVID-19 (dose and duration not specified). Cases 1 and 2 in our institution also seemed to have the same pattern of PJP superinfection, even if case 2 had a previous history of glucocorticoid therapy not related to COVID-19.
The third pattern of presentation is P. jirovecii coinfection, resulting in progressive multilobar pneumonia. In most of these patients, long-term exposure to immunosuppressants or a severe immunodeficiency were present as PJP risk factors. In the present review, more than half of patients were immunocompromised at the baseline. These patients frequently presented with worsening of respiratory illness despite the treatment for COVID-19, while their clinical and radiological presentations were suggestive of PJP. Case 3 in our institution seemed to have this pattern of PJP.
In immunocompromised patients, COVID-19 is more likely to be severe [74,75,76], and concurrent IFIs should be considered in the differential diagnosis. Numerous case reports and observational studies have highlighted that fungal superinfection can complicate the clinical course of COVID-19 [77]. Although patients with IFI are expected to have underlying immunodeficiency, some data showed that patients with COVID-19 may develop IFI without preexisting immunodeficiency. The data available so far show that in concurrent IFIs, such as COVID-19 pneumonia associated pulmonary aspergillosis (CAPA), the classical IFI host risk factors may not be present [78,79]. Mortality in CAPA patients seems to be higher when compared to mortality in no-CAPA patients [21,80]. Treatment with glucocorticoids and tocilizumab for COVID-19 pneumonia may increase the risk of infection with Aspergillus spp. infection in severe COVID-19 patients [22].
According to the current guidelines, glucocorticoids are systematically administered to severe COVID-19 patients for 10 days or upon discharge [17,81]. Patients with a slow response to glucocorticoids may receive a long duration of treatment, which gradually enhances the risk of PJP. Other immunosuppressive drugs used to manage COVID-19 (e.g., baricitinib, tocilizumab) also increase the risk of PJP.
Notably, almost all patients in this review received systemic glucocorticoid therapy as COVID-19 treatment. One observational study by Alanio et al. [34] observed that long-term corticosteroid prescription tended to be more frequent in patients with a positive P. jirovecii PCR (30.0% vs. 8.2%, p = 0.06). This finding highlighted the role of glucocorticoid therapy in the development of PJP.
PJP is commonly associated with prolonged courses of corticosteroids (4 weeks), with a median daily dose equivalent to 30 mg of prednisone [82]. However, patients receiving doses as low as 15 mg or having baseline lymphopenia are also at risk [83]. Immunosuppression from glucocorticoids and severe COVID-19-related lymphopenia may increase the risk of SARS-CoV-2 and P. jirovecii concurrent infection and may occur even in individuals outside classical known risk groups. In previously colonized patients, these factors may also activate the ongoing infection with P. jirovecii, leading to the development of PJP.
Probably, in P. jirovecii superinfection, glucocorticoid therapy prescribed for COVID-19 and lymphopenia are the most important PJP risk factors (Table 2). COVID-19 patients with P. jirovecii airway colonization are at risk of biphasic pneumonia (i.e., superinfection), and anti-pneumocystis prophylaxis should be considered in case of prolonged glucocorticoid therapy or severe lymphopenia.
In addition, anti-pneumocystis prophylaxis should be considered during COVID-19 hospitalization of patients with classical PJP risk factors.

5. Conclusions

The diagnosis of PJP in patients with SARS-CoV-2 infection seems to be considerably underestimated, since the diagnosis of COVID-19 does not require BAL. Patients with concomitant PJP and COVID-19 do not necessarily have preexisting immunodeficiency. Patients with severe COVID-19 frequently develop CD4+ lymphocytopenia. They routinely require treatment with glucocorticoids and other immunosuppressive agents. Thus, severe COVID-19 appears to increase the risk of PJP. We demonstrated that detection of P. jirovecii in patients with COVID-19 can be characterized into three important categories (i.e., airway colonization, coinfection, and superinfection). Patients with severe COVID-19 and P. jirovecii colonization may require anti-pneumocystis prophylaxis. Observational and prospective studies are required to determine the risk of PJP in patients with moderate to severe COVID-19, considering different level of lymphopenia.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jof8060585/s1, Data S1: Full search strategies.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Alanio, A.; Bretagne, S. Pneumocystis Jirovecii Detection in Asymptomatic Patients: What Does Its Natural History Tell Us? F1000Research 2017, 6, 739. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Vera, C.; Rueda, Z.V. Transmission and Colonization of Pneumocystis Jirovecii. J. Fungi 2021, 7, 979. [Google Scholar] [CrossRef] [PubMed]
  3. Vargas, S.L.; Ponce, C.; Bustamante, R.; Calderón, E.; Nevez, G.; De Armas, Y.; Matos, O.; Miller, R.F.; Gallo, M.J. Importance of Tissue Sampling, Laboratory Methods, and Patient Characteristics for Detection of Pneumocystis in Autopsied Lungs of Non-Immunosuppressed Individuals. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 1711–1716. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Medrano, F.J.; Montes-Cano, M.; Conde, M.; de la Horra, C.; Respaldiza, N.; Gasch, A.; Perez-Lozano, M.J.; Varela, J.M.; Calderon, E.J. Pneumocystis Jirovecii in General Population. Emerg. Infect. Dis. 2005, 11, 245–250. [Google Scholar] [CrossRef] [PubMed]
  5. Vargas, S.L.; Ponce, C.A.; Sanchez, C.A.; Ulloa, A.V.; Bustamante, R.; Juarez, G. Pregnancy and Asymptomatic Carriage of Pneumocystis Jiroveci. Emerg. Infect. Dis. 2003, 9, 605–606. [Google Scholar] [CrossRef]
  6. Ponce, C.A.A.; Gallo, M.; Bustamante, R.; Vargas, S.L.L. Pneumocystis Colonization Is Highly Prevalent in the Autopsied Lungs of the General Population. Clin. Infect. Dis. 2010, 50, 347–353. [Google Scholar] [CrossRef] [Green Version]
  7. Djawe, K.; Daly, K.R.; Vargas, S.L.; Santolaya, M.E.; Ponce, C.A.; Bustamante, R.; Koch, J.; Levin, L.; Walzer, P.D. Seroepidemiological Study of Pneumocystis Jirovecii Infection in Healthy Infants in Chile Using Recombinant Fragments of the P. Jirovecii Major Surface Glycoprotein. Int. J. Infect. Dis. 2010, 14, e1060–e1066. [Google Scholar] [CrossRef] [Green Version]
  8. Monroy-Vaca, E.X.; de Armas, Y.; Illnait-Zaragozí, M.T.; Toraño, G.; Diaz, R.; Vega, D.; Alvarez-Lam, I.; Calderón, E.J.; Stensvold, C.R. Prevalence and Genotype Distribution of Pneumocystis Jirovecii in Cuban Infants and Toddlers with Whooping Cough. J. Clin. Microbiol. 2014, 52, 45–51. [Google Scholar] [CrossRef] [Green Version]
  9. Vargas, S.L.; Hughes, W.T.; Santolaya, M.E.; Ulloa, A.V.; Ponce, C.A.; Cabrera, C.E.; Cumsille, F.; Gigliotti, F. Search for Primary Infection by Pneumocystis Carinii in a Cohort of Normal, Healthy Infants. Clin. Infect. Dis. 2001, 32, 855–861. [Google Scholar] [CrossRef] [Green Version]
  10. Respaldiza, N.; Medrano, F.J.; Medrano, A.C.; Varela, J.M.; de la Horra, C.; Montes-Cano, M.; Ferrer, S.; Wichmann, I.; Gargallo-Viola, D.; Calderon, E.J. High Seroprevalence of Pneumocystis Infection in Spanish Children. Clin. Microbiol. Infect. 2004, 10, 1029–1031. [Google Scholar] [CrossRef] [Green Version]
  11. Avino, L.J.; Naylor, S.M.; Roecker, A.M. Pneumocystis Jirovecii Pneumonia in the Non–HIV-Infected Population. Ann. Pharmacother. 2016, 50, 673–679. [Google Scholar] [CrossRef] [PubMed]
  12. Peter Donnelly, J.; Chen, S.C.; Kauffman, C.A.; Steinbach, W.J.; Baddley, J.W.; Verweij, P.E.; Clancy, C.J.; Wingard, J.R.; Lockhart, S.R.; Groll, A.H.; et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin. Infect. Dis. 2020, 71, 1367–1376. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Hall, M.W.; Joshi, I.; Leal, L.; Ooi, E.E. Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention. Clin. Infect. Dis. 2022, 74, 144–148. [Google Scholar] [CrossRef] [PubMed]
  14. Giamarellos-Bourboulis, E.J.; Netea, M.G.; Rovina, N.; Akinosoglou, K.; Antoniadou, A.; Antonakos, N.; Damoraki, G.; Gkavogianni, T.; Adami, M.-E.; Katsaounou, P.; et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe 2020, 27, 992–1000.e3. [Google Scholar] [CrossRef] [PubMed]
  15. Rawson, T.M.; Moore, L.S.P.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. 2020, 71, 2459–2468. [Google Scholar] [CrossRef]
  16. Ripa, M.; Galli, L.; Poli, A.; Oltolini, C.; Spagnuolo, V.; Mastrangelo, A.; Muccini, C.; Monti, G.; De Luca, G.; Landoni, G.; et al. Secondary Infections in Patients Hospitalized with COVID-19: Incidence and Predictive Factors. Clin. Microbiol. Infect. 2021, 27, 451–457. [Google Scholar] [CrossRef] [PubMed]
  17. RECOVERY Collaborative Group; Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; et al. Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021, 384, 693–704. [Google Scholar] [CrossRef]
  18. Sterne, J.A.C.; Murthy, S.; Diaz, J.V.; Slutsky, A.S.; Villar, J.; Angus, D.C.; Annane, D.; Azevedo, L.C.P.; Berwanger, O.; Cavalcanti, A.B.; et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. JAMA 2020, 324, 1330. [Google Scholar] [CrossRef]
  19. Hughes, S.; Troise, O.; Donaldson, H.; Mughal, N.; Moore, L.S.P. Bacterial and Fungal Coinfection among Hospitalized Patients with COVID-19: A Retrospective Cohort Study in a UK Secondary-Care Setting. Clin. Microbiol. Infect. 2020, 26, 1395–1399. [Google Scholar] [CrossRef]
  20. Baddley, J.W.; Thompson, G.R.; Chen, S.C.-A.; White, P.L.; Johnson, M.D.; Nguyen, M.H.; Schwartz, I.S.; Spec, A.; Ostrosky-Zeichner, L.; Jackson, B.R.; et al. Coronavirus Disease 2019–Associated Invasive Fungal Infection. Open Forum Infect. Dis. 2021, 8. [Google Scholar] [CrossRef]
  21. Feys, S.; Almyroudi, M.P.; Braspenning, R.; Lagrou, K.; Spriet, I.; Dimopoulos, G.; Wauters, J. A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA). J. Fungi 2021, 7, 1067. [Google Scholar] [CrossRef] [PubMed]
  22. Gangneux, J.-P.; Dannaoui, E.; Fekkar, A.; Luyt, C.-E.; Botterel, F.; De Prost, N.; Tadié, J.-M.; Reizine, F.; Houzé, S.; Timsit, J.-F.; et al. Fungal Infections in Mechanically Ventilated Patients with COVID-19 during the First Wave: The French Multicentre MYCOVID Study. Lancet Respir. Med. 2022, 10, 180–190. [Google Scholar] [CrossRef]
  23. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J.; HLH Across Speciality Collaboration. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet 2020, 395, 1033–1034. [Google Scholar] [CrossRef]
  24. Garcia-Vidal, C.; Sanjuan, G.; Moreno-García, E.; Puerta-Alcalde, P.; Garcia-Pouton, N.; Chumbita, M.; Fernandez-Pittol, M.; Pitart, C.; Inciarte, A.; Bodro, M.; et al. Incidence of Co-Infections and Superinfections in Hospitalized Patients with COVID-19: A Retrospective Cohort Study. Clin. Microbiol. Infect. 2021, 27, 83–88. [Google Scholar] [CrossRef]
  25. Hoenigl, M. Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores. Clin. Infect. Dis. An Off. Publ. Infect. Dis. Soc. Am. 2021, 73, e1645. [Google Scholar] [CrossRef]
  26. Gangneux, J.-P.P.; Bougnoux, M.-E.E.; Dannaoui, E.; Cornet, M.; Zahar, J.R.R. Invasive Fungal Diseases during COVID-19: We Should Be Prepared. J. Mycol. Med. 2020, 30, 100971. [Google Scholar] [CrossRef]
  27. Song, G.; Liang, G.; Liu, W. Fungal Co-Infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia 2020, 185, 599–606. [Google Scholar] [CrossRef]
  28. Koehler, P.; Cornely, O.A.; Böttiger, B.W.; Dusse, F.; Eichenauer, D.A.; Fuchs, F.; Hallek, M.; Jung, N.; Klein, F.; Persigehl, T.; et al. COVID-19 Associated Pulmonary Aspergillosis. Mycoses 2020, 63, 528–534. [Google Scholar] [CrossRef]
  29. Chong, W.H.; Saha, B.K.; Chopra, A. Narrative Review of the Relationship between COVID-19 and PJP: Does It Represent Coinfection or Colonization? Infection 2021, 49, 1079–1090. [Google Scholar] [CrossRef]
  30. Jeican, I.I.; Inișca, P.; Gheban, D.; Tăbăran, F.; Aluaș, M.; Trombitas, V.; Cristea, V.; Crivii, C.; Junie, L.M.; Albu, S. COVID-19 and Pneumocystis Jirovecii Pulmonary Coinfection—The First Case Confirmed through Autopsy. Medicina 2021, 57, 302. [Google Scholar] [CrossRef]
  31. Kelly, S.; Waters, L.; Cevik, M.; Collins, S.; Lewis, J.; Wu, M.-S.S.; Blanchard, T.J.; Geretti, A.M. Pneumocystis Pneumonia, a COVID-19 Mimic, Reminds Us of the Importance of HIV Testing in COVID-19. Clin. Med. J. R. Coll. Physicians 2020, 20, 590–592. [Google Scholar] [CrossRef]
  32. Sasso, M.; Chastang-Dumas, E.; Bastide, S.; Alonso, S.; Lechiche, C.; Bourgeois, N.; Lachaud, L. Performances of Four Real-Time PCR Assays for Diagnosis of Pneumocystis Jirovecii Pneumonia. J. Clin. Microbiol. 2016, 54, 625–630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Cruciani, M.; Marcati, P.; Malena, M.; Bosco, O.; Serpelloni, G.; Mengoli, C. Meta-Analysis of Diagnostic Procedures for Pneumocystis Carinii Pneumonia in HIV-1-Infected Patients. Eur. Respir. J. 2002, 20, 982–989. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Alanio, A.; Dellière, S.; Voicu, S.; Bretagne, S.; Mégarbane, B. The Presence of Pneumocystis Jirovecii in Critically Ill Patients with COVID-19. J. Infect. 2021, 82, 84–123. [Google Scholar] [CrossRef]
  35. Menon, A.A.; Berg, D.D.; Brea, E.J.; Deutsch, A.J.; Kidia, K.K.; Thurber, E.G.; Polsky, S.B.; Yeh, T.; Duskin, J.A.; Holliday, A.M.; et al. A Case of COVID-19 and Pneumocystis Jirovecii Coinfection. Am. J. Respir. Crit. Care Med. 2020, 202, 136–138. [Google Scholar] [CrossRef]
  36. Mang, S.; Kaddu-Mulindwa, D.; Metz, C.; Becker, A.; Seiler, F.; Smola, S.; Maßmann, A.; Becker, S.L.; Papan, C.; Bals, R.; et al. Pneumocystis Jirovecii Pneumonia and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection in a Patient With Newly Diagnosed HIV-1 Infection. Clin. Infect. Dis. 2021, 72, 1487–1489. [Google Scholar] [CrossRef]
  37. Coleman, H.; Snell, L.B.; Simons, R.; Douthwaite, S.T.; Lee, M.J. Coronavirus Disease 2019 and Pneumocystis Jirovecii Pneumonia: A Diagnostic Dilemma in HIV. AIDS 2020, 34, 1258–1260. [Google Scholar] [CrossRef]
  38. Bhat, P.; Noval, M.; Doub, J.B.; Heil, E. Concurrent COVID-19 and Pneumocystis Jirovecii Pneumonia in a Severely Immunocompromised 25-Year-Old Patient. Int. J. Infect. Dis. 2020, 99, 119–121. [Google Scholar] [CrossRef]
  39. De Francesco, M.A.; Alberici, F.; Bossini, N.; Scolari, F.; Pascucci, F.; Tomasoni, G.; Caruso, A. Pneumocystis Jirevocii and SARS-CoV-2 Co-Infection: A Common Feature in Transplant Recipients? Vaccines 2020, 8, 544. [Google Scholar] [CrossRef]
  40. Gerber, V.; Ruch, Y.; Chamaraux-Tran, T.-N.N.; Oulehri, W.; Schneider, F.; Lindner, V.; Greigert, V.; Denis, J.; Brunet, J.; Danion, F. Detection of Pneumocystis Jirovecii in Patients with Severe COVID-19: Diagnostic and Therapeutic Challenges. J. Fungi 2021, 7, 585. [Google Scholar] [CrossRef]
  41. Kronsten, V.T.; Patel, S.; Pirani, T.; Aluvihare, V.; Agarwal, K. Co-Infection with SARS-CoV-2 and Pneumocystis Jirovecii in Liver Transplant Recipients: A Double Whammy. J. Liver Transplant. 2021, 4, 100047. [Google Scholar] [CrossRef]
  42. Gentile, I.; Viceconte, G.; Lanzardo, A.; Zotta, I.; Zappulo, E.; Pinchera, B.; Scotto, R.; Moriello, N.S.; Foggia, M.; Giaccone, A.; et al. Pneumocystis Jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. Int. J. Environ. Res. Public Health 2021, 18, 11399. [Google Scholar] [CrossRef] [PubMed]
  43. Cai, S.; Sun, W.; Li, M.; Dong, L. A Complex COVID-19 Case with Rheumatoid Arthritis Treated with Tocilizumab. Clin. Rheumatol. 2020, 39, 2797–2802. [Google Scholar] [CrossRef] [PubMed]
  44. Broadhurst, A.G.B.; Lalla, U.; Taljaard, J.J.; Louw, E.H.; Koegelenberg, C.F.N.; Allwood, B.W. The Diagnostic Challenge of Pneumocystis Pneumonia and COVID-19 Co-Infection in HIV. Respirol. Case Rep. 2021, 9, e00725. [Google Scholar] [CrossRef] [PubMed]
  45. Rubiano, C.; Tompkins, K.; Sellers, S.A.; Bramson, B.; Eron, J.; Parr, J.B.; Schranz, A.J. Pneumocystis and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Case Report and Review of an Emerging Diagnostic Dilemma. Open Forum Infect. Dis. 2021, 8. [Google Scholar] [CrossRef]
  46. Viceconte, G.; Buonomo, A.R.; Lanzardo, A.; Pinchera, B.; Zappulo, E.; Scotto, R.; Schiano Moriello, N.; Vargas, M.; Iacovazzo, C.; Servillo, G.; et al. Pneumocystis Jirovecii Pneumonia in an Immunocompetent Patient Recovered from COVID-19. Infect. Dis. (Auckl). 2021, 53, 382–385. [Google Scholar] [CrossRef]
  47. Larzábal, F.J.; Vilela, A.; Brusca, S.; Saluzzi, I.; Ghergo, G.E.; Angiono, M.A. [Simultaneous Diagnosis and Favorable Evolution of Infection with Pneumocystis Jirovecii, SARS-CoV-2 and Advanced HIV]. Medicina 2020, 80, 554–556. [Google Scholar]
  48. Peng, J.; Ni, M.; Du, D.; Lu, Y.; Song, J.; Liu, W.; Shen, N.; Wang, X.; Zhu, Y.; Vallance, B.A.; et al. Successful Treatment of a Kidney Transplant Patient with COVID-19 and Late-Onset Pneumocystis Jirovecii Pneumonia. Ann. Clin. Microbiol. Antimicrob. 2021, 20, 1–7. [Google Scholar] [CrossRef]
  49. Mouren, D.; Goyard, C.; Catherinot, E.; Givel, C.; Chabrol, A.; Tcherakian, C.; Longchampt, E.; Vargaftig, J.; Farfour, E.; Legal, A.; et al. COVID-19 and Pneumocystis Jirovecii Pneumonia: Back to the Basics. Respir. Med. Res. 2021, 79, 100814. [Google Scholar] [CrossRef]
  50. Quintana-Ortega, C.; Remesal, A.; Ruiz de Valbuena, M.; de la Serna, O.; Laplaza-González, M.; Álvarez-Rojas, E.; Udaondo, C.; Alcobendas, R.; Murias, S. Fatal Outcome of Anti-MDA5 Juvenile Dermatomyositis in a Paediatric COVID-19 Patient: A Case Report. Mod. Rheumatol. Case Rep. 2021, 5, 101–107. [Google Scholar] [CrossRef]
  51. Anggraeni, A.T.; Soedarsono, S.; Soeprijanto, B. Concurrent COVID-19 and Pneumocystis Jirovecii Pneumonia: The Importance of Radiological Diagnostic and HIV Testing. Radiol. Case Rep. 2021, 16, 3685–3689. [Google Scholar] [CrossRef]
  52. Algarín-Lara, H.; Osorio-Rodríguez, E.; Patiño-Patiño, J.; Mendoza-Morales, I.; Rodado-Villa, R. Neumonía Por SARS-CoV-2 Asociado a Coinfección Por Pneumocystis Jirovecii En Paciente Inmunocomprometido: A Propósito de Un Caso y Revisión de La Literatura. Acta Colomb. Cuid. Intensivo 2021. [Google Scholar] [CrossRef]
  53. Merchant, E.A.; Flint, K.; Barouch, D.H.; Blair, B.M. Co-Infection with Coronavirus Disease 2019, Previously Undiagnosed Human Immunodeficiency Virus, Pneumocystis Jirovecii Pneumonia and Cytomegalovirus Pneumonitis, with Possible Immune Reconstitution Inflammatory Syndrome. IDCases 2021, 24, e01153. [Google Scholar] [CrossRef] [PubMed]
  54. Blaize, M.; Mayaux, J.; Luyt, C.E.; Lampros, A.; Fekkar, A. COVID-19–Related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis. Am. J. Respir. Crit. Care Med. 2021, 202, 1734–1736. [Google Scholar] [CrossRef] [PubMed]
  55. Barben, J.; Quipourt, V.; Vovelle, J.; Putot, A.; Manckoundia, P. Not COVID-19, Don’t Overlook Pneumocystis in Patients on Gefitinib! Curr. Oncol. 2021, 28, 961–964. [Google Scholar] [CrossRef]
  56. Lim, W.; Suhail, M.; Diaz, K. Diagnostic Challenges of Pneumocystis Pneumonia during the COVID-19 Pandemic: A Case of a Young Patient with Ground Glass Opacities and Pulmonary Embolism on Chest CT. Case Rep. Infect. Dis. 2021, 2021, 1–6. [Google Scholar] [CrossRef]
  57. Parker, A.; Shaw, J.; Karamchand, S.; Lahri, S.; Schrueder, N.; Chothia, M.-Y.; Mowlana, A.; Lalla, U.; Allwood, B.W.; Koegelenberg, C.F.N.; et al. HIV and SARS-CoV-2 Co-Infection: The Diagnostic Challenges of Dual Pandemics. S. Afr. Med. J. 2020, 110, 473–475. [Google Scholar] [CrossRef]
  58. Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hesketh, R.L.; Yang, L.; et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020, 295, 715–721. [Google Scholar] [CrossRef] [Green Version]
  59. Hidalgo, A.; Falcó, V.; Mauleón, S.; Andreu, J.; Crespo, M.; Ribera, E.; Pahissa, A.; Cáceres, J. Accuracy of High-Resolution CT in Distinguishing between Pneumocystis Carinii Pneumonia and Non-Pneumocystis Carinii Pneumonia in AIDS Patients. Eur. Radiol. 2003, 13, 1179–1184. [Google Scholar] [CrossRef]
  60. Parekh, M.; Donuru, A.; Balasubramanya, R.; Kapur, S. Review of the Chest CT Differential Diagnosis of Ground-Glass Opacities in the COVID Era. Radiology 2020, 297, E289–E302. [Google Scholar] [CrossRef]
  61. Bernheim, A.; Mei, X.; Huang, M.; Yang, Y.; Fayad, Z.A.; Zhang, N.; Diao, K.; Lin, B.; Zhu, X.; Li, K.; et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology 2020, 295, 200463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Hardak, E.; Brook, O.; Yigla, M. Radiological Features of Pneumocystis Jirovecii Pneumonia in Immunocompromised Patients with and Without AIDS. Lung 2010, 188, 159–163. [Google Scholar] [CrossRef] [PubMed]
  63. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [Green Version]
  64. Tan, L.; Wang, Q.; Zhang, D.; Ding, J.; Huang, Q.; Tang, Y.-Q.; Wang, Q.; Miao, H. Lymphopenia Predicts Disease Severity of COVID-19: A Descriptive and Predictive Study. Signal Transduct. Target. Ther. 2020, 5, 33. [Google Scholar] [CrossRef] [PubMed]
  65. Werbel, W.A.; Ison, M.G.; Angarone, M.P.; Yang, A.; Stosor, V. Lymphopenia Is Associated with Late Onset Pneumocystis Jirovecii Pneumonia in Solid Organ Transplantation. Transpl. Infect. Dis. 2018, 20, e12876. [Google Scholar] [CrossRef]
  66. Messiaen, P.E.; Cuyx, S.; Dejagere, T.; van der Hilst, J.C. The Role of CD4 Cell Count as Discriminatory Measure to Guide Chemoprophylaxis against Pneumocystis Jirovecii Pneumonia in Human Immunodeficiency Virus-Negative Immunocompromised Patients: A Systematic Review. Transpl. Infect. Dis. 2017, 19, e12651. [Google Scholar] [CrossRef] [PubMed]
  67. Eddens, T.; Campfield, B.T.; Serody, K.; Manni, M.L.; Horne, W.; Elsegeiny, W.; McHugh, K.J.; Pociask, D.; Chen, K.; Zheng, M.; et al. A Novel CD4 + T Cell–Dependent Murine Model of Pneumocystis -Driven Asthma-like Pathology. Am. J. Respir. Crit. Care Med. 2016, 194, 807–820. [Google Scholar] [CrossRef] [Green Version]
  68. Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; Yang, S.; Tao, Y.; Xie, C.; Ma, K.; Shang, K.; Wang, W.; et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020, 71, 762–768. [Google Scholar] [CrossRef]
  69. Thomas, C.F.; Limper, A.H. Pneumocystis Pneumonia. N. Engl. J. Med. 2004, 350, 2487–2498. [Google Scholar] [CrossRef]
  70. Bertuzzi, M.; Hayes, G.; Icheoku, U.; van Rhijn, N.; Denning, D.; Osherov, N.; Bignell, E. Anti-Aspergillus Activities of the Respiratory Epithelium in Health and Disease. J. Fungi 2018, 4, 8. [Google Scholar] [CrossRef] [Green Version]
  71. Kottom, T.J.; Hebrink, D.M.; Limper, A.H. Binding of Pneumocystis Carinii to the Lung Epithelial Cell Receptor HSPA5 (GRP78). J. Med. Microbiol. 2018, 67, 1772–1777. [Google Scholar] [CrossRef] [PubMed]
  72. Beumer, M.C.; Koch, R.M.; van Beuningen, D.; OudeLashof, A.M.; van de Veerdonk, F.L.; Kolwijck, E.; van der Hoeven, J.G.; Bergmans, D.C.; Hoedemaekers, C.W.E. Influenza Virus and Factors That Are Associated with ICU Admission, Pulmonary Co-Infections and ICU Mortality. J. Crit. Care 2019, 50, 59–65. [Google Scholar] [CrossRef] [PubMed]
  73. Abdoli, A.; Falahi, S.; Kenarkoohi, A. COVID-19-Associated Opportunistic Infections: A Snapshot on the Current Reports. Clin. Exp. Med. 2021. [Google Scholar] [CrossRef] [PubMed]
  74. Fung, M.; Babik, J.M. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin. Infect. Dis. 2021, 72, 340–350. [Google Scholar] [CrossRef] [PubMed]
  75. Goldman, J.D.; Robinson, P.C.; Uldrick, T.S.; Ljungman, P. COVID-19 in Immunocompromised Populations: Implications for Prognosis and Repurposing of Immunotherapies. J. Immunother. Cancer 2021, 9, e002630. [Google Scholar] [CrossRef]
  76. Colmenero, J.; Rodríguez-Perálvarez, M.; Salcedo, M.; Arias-Milla, A.; Muñoz-Serrano, A.; Graus, J.; Nuño, J.; Gastaca, M.; Bustamante-Schneider, J.; Cachero, A.; et al. Epidemiological Pattern, Incidence, and Outcomes of COVID-19 in Liver Transplant Patients. J. Hepatol. 2021, 74, 148–155. [Google Scholar] [CrossRef]
  77. Casalini, G.; Giacomelli, A.; Ridolfo, A.; Gervasoni, C.; Antinori, S. Invasive Fungal Infections Complicating COVID-19: A Narrative Review. J. Fungi 2021, 7, 921. [Google Scholar] [CrossRef]
  78. Janssen, N.A.F.; Nyga, R.; Vanderbeke, L.; Jacobs, C.; Ergün, M.; Buil, J.B.; van Dijk, K.; Altenburg, J.; Bouman, C.S.C.; van der Spoel, H.I.; et al. Multinational Observational Cohort Study of COVID-19–Associated Pulmonary Aspergillosis1. Emerg. Infect. Dis. 2021, 27, 2892–2898. [Google Scholar] [CrossRef]
  79. Ergün, M.; Brüggemann, R.J.M.; Alanio, A.; Dellière, S.; van Arkel, A.; Bentvelsen, R.G.; Rijpstra, T.; van der Sar-van der Brugge, S.; Lagrou, K.; Janssen, N.A.F.; et al. Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. J. Clin. Microbiol. 2021, 59, e0122921. [Google Scholar] [CrossRef]
  80. Prattes, J.; Wauters, J.; Giacobbe, D.R.; Salmanton-García, J.; Maertens, J.; Bourgeois, M.; Reynders, M.; Rutsaert, L.; Van Regenmortel, N.; Lormans, P.; et al. Risk Factors and Outcome of Pulmonary Aspergillosis in Critically Ill Coronavirus Disease 2019 Patients—a Multinational Observational Study by the European Confederation of Medical Mycology. Clin. Microbiol. Infect. 2021. [Google Scholar] [CrossRef]
  81. Tleyjeh, I.M.; Kashour, Z.; Damlaj, M.; Riaz, M.; Tlayjeh, H.; Altannir, M.; Altannir, Y.; Al-Tannir, M.; Tleyjeh, R.; Hassett, L.; et al. Efficacy and Safety of Tocilizumab in COVID-19 Patients: A Living Systematic Review and Meta-Analysis. Clin. Microbiol. Infect. 2021, 27, 215–227. [Google Scholar] [CrossRef] [PubMed]
  82. Park, J.W.; Curtis, J.R.; Kim, M.J.; Lee, H.; Song, Y.W.; Lee, E.B. Pneumocystis Pneumonia in Patients with Rheumatic Diseases Receiving Prolonged, Non-High-Dose Steroids—Clinical Implication of Primary Prophylaxis Using Trimethoprim–Sulfamethoxazole. Arthritis Res. Ther. 2019, 21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Yale, S.H.; Limper, A.H. Pneumocystis Carinii Pneumonia in Patients Without Acquired Immunodeficiency Syndrome: Associated Illnesses and Prior Corticosteroid Therapy. Mayo Clin. Proc. 1996, 71, 5–13. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Demographic and clinical characteristic of patients.
Table 1. Demographic and clinical characteristic of patients.
Authors and Type of StudyN of CasesSex, AgeComorbiditiesImmunosuppressionRadiological FindingsACL/CD4+Diagnostic Tests for PJPDiagnosis
EORT/MSG Cirteria		PJP Treatment, Outcome
Alanio et al. [34]
Prospective observational study
2020		108 M,
Mean age 59		DM: 3, AHT: 6, Obesity: 3,
CVD:1, Asthma: 1		Long-term Steroid therapy: 3NRNRPCR on RSProbable PJPTMP-SMX: 4
IMV: 10
Died: 3
Menon et al. [35]
Case report
2020		1F, 83CVD, AsthmaUlcertive Colitis,
Long-term Steroid therapy		GGO
Cystic
Consolidation		1090/290RT-PCR on TA
BDG (305 pg/mL)		Probable PJPTMP-SMX
IMV
Survived
Mang et al. [36]
Case report
2020		1M, 52AHT, Obesity,
HIV		AIDSGGO
Crazy paving		590/12PCR on TAProbable PJPTMP-SMX
Prednisone
IMV
Survived
Coleman et al. [37]
Case report
2020		1M, 54HIV, AsthmaNoneGGO
Cystic		NR/422PCR on induced sputumProbable PJPTMP-SMX
Prednisone
no IMV
Survived
Bhat et al. [38]
Case report
2020		1M, 25HIVAIDSGGO
Cyst
pneumothorax		NR/32IFM on BALProbable PJPTMP-SMX
Prednisone
IMV
Survived
De Franceso et al. [39]
Case report
2020		1M, 65DM, AHT
CVD, SOT		SOT (kidney), Long-term steroid therapyGGONR/422PCR on sputumProbable PJPTMP-SMX
Prednisone
IMV
Died
Gerber et al. [40]
Case series
2020		4F, 80Obesity
RA		RA
Long-term Steroid therapy		GGO
Consolidation
Nodules		300/NRPCR on BALProbable PJPTMP-SMX
IMV
Died
M, 70Obesity, CKD, Hematological cancerHSCTGGO consolidation222/NRPCR on TAProbable PJPTMP-SMX
IMV
Died
M, 83CVD, CKD
Asthma		NoneGGO
Crazy paving		570/NRPCR and cytology on BALProven PJPTMP-SMX
No IMV
Died
M, 80DM, AHT
CVD, Asthma		NoneGGO
Pleural effusion		600/NRPCR on TAProbable PJPTMP-SMX
IMV
Died
Kronsten VT et al. [41]
Case series
2021		2M, 28DM
SOT		Liver transplant
Long-term Steroid therapy		GGO360/NRPCR on BAL
BDG on BAL 226 pg/mL		Probable PJPTMP-SMX
IMV
Survived
M, 54SOTLiver transplant
Long-term Steroid therapy		GGO390/NRPCR on BAL
BDG on BAL 227 pg/mL		Probable PJPTMP-SMX
IMV
Survived
Gentile I et al. [42]
Case series
2021		4M, 55NoneLong-term Steroid therapyGGO260/62IFM on BALProbable PJPTMP-SMX
No IMV
Survived
M, 75AHT
CVD		Long-term Steroid therapyGGO2220/1021NonePossible PJPTMP-SMX
No IMV
Survived
F, 63NHLNHL
Long-term Steroid therapy		GGO240/93IFM on BALProbable PJPTMP-SMX
No IMV
Survived
M, 68NoneLong-term Steroid therapyGGO
Pleural effusion		560/141NonePossible PJPTMP-SMX
No IMV
Survived
Cai et al. [43]
Case report
2020		1M, 72RARA
Long-term Steroid therapy		GGO
Acute consolidation		340/NRNonePossible PJPCaspofungin
No IMV
Survived
Broadhurst et al. [44]
Case report
2021		1M, 54DM
AHT
HIV		AIDSGGO690/26IFM on sputum
BDG (>500 pg/mL)		Probable PJPTMP-SMX
No IMV
Died
Jeican et al. [30]
Case report
2021		1M, 52AHT
CVD
Liver disease		NoneConsolidation190/NRPositive histopathologyProven PJPNone
No IMV
Died
Rubiano et al. [45]
Case report
2021		1M, 36HIVAIDSGGO400/8PCR and IFM on BAL
BDG (>500 pg/mL)		Probable PJPTMP-SMX
IMV
Died
Viceconte et al. [46]
Case report
2021		1M, 54NoneLong-term Steroid therapyGGO
Consolidation		1265/895IFM on BAL
BDG positive		Probable PJPTMP-SMX
No IMV
Survived
Larzábal et al. [47]
Case report 2020		1F, 46Raynaud syndrome
HIV		AIDSConsolidationNR/67IFM sputumProbable PJPTMP-SMX
No IMV
Survived
Peng et al. [48]
Case report
2020		1F, 55CVD
SOT		SOT (kidney)
Long-term Steroid therapy		Consolidation310/258PCR on sputum
BDG (89.3 pg/mL)		Probable PJPMicafungin
No IMV
Survived
Mouren et al. [49]
Case report
2020		1M, 65Hematological malignancy CLLCLLGGO200/NRPCR and IFM on BALProbable PJPTMP-SMX
No IMV
Survived
Quintana-Ortega et al. [50]
Case report
2021		1F, 11DermatomyositisDermatomyositis
Long term Steroid therapy		GGO110/NRIFM on BALProbable PJPTMP-SMX
IMV
Died
Anggraeni AT et al. [51]
Case report
2021		1M, 24HIVAIDSGGO176/16nonePossible PJPTMP-SMX
No IMV
Survived
Algarín-Lara H et al. [52]
Case report
2021		1M, 63Obesity
HIV		AIDSGGONR/84PCR on BALProbable PJPTMP-SMX
IMV
Died
Merchant EA et al. [53]
Case report
2021		1M, 39HIVAIDSGGO860/1IFM on BALProbable PJPTMP-SMX
IMV
Died
Blaize et al. [54]
Observational study
2020		2F, 38DM
AHT		noneGGONRPCR on BALProbable PJPNone
IMV
Died
F/NRDM
AHT
Obesity		noneGGONRPCR on BALProbable PJPNone
IMV
Died
Abbreviations: AHT: Arterial hypertension, AIDS: acquired immunodeficiency syndrome, BDG: Beta-D-Glucan, CDK: chronic kidney disease, CVD: chronic vascular disease, DM: diabetes mellitus, GGO: ground glass opacity, HIV: Human Inmunodeficency virus, IFM: immunofluorescence microscopy, IMV: invasive mechanical ventilation, NR: not reported, RA: SOT: solid organ transplant, and TA: tracheal aspirate.
Table
Table 2. Patterns of COVID-19 and P. jirovecii colonization, coinfection, and superinfection.
Table 2. Patterns of COVID-19 and P. jirovecii colonization, coinfection, and superinfection.
PatternsCase ClassificationP. jirovecii Load (PCR)Clinical CourseRadiographic Characteristics
Airway colonizationBlaize et al. [54]
Alanio et al. [34] 		<1000 copies/mLTypical course of COVID-19Similar to COVID-19
Grand-glass opacity
SuperinfectionGerber et al. [40]
Gentile et al. [42]
Cai et al. [43]
Viceconte et al. [46]
Peng et al. [48]
Mouren et al. [49]
Merchant EA et al. [53]
Case 1 and 2 in our institution		>1000 copies/mLBiphasic illness.
The first phase is related to COVID-19, followed by clinical improvement. Subsequently, the second phase of respiratory illness (PJP) starts days or weeks later. 		Similar to COVID-19
Diffuse, bilateral, interstitial infiltrates
Grand-glass opacity
Cysts, lobar infiltrates
Solitary or multiple nodules
CoinfectionMenon et al. [35]
Mang et al. [36]
Coleman et al. [37]
Bhat et al. [38]
De Franceso et al. [39]
Kronsten VT et al. [41]
Broadhurst et al. [44]
Jeican et al. [30]
Rubiano et al. [45]
Larzábal et al. [47]
Anggraeni et al. [51]
Cases 3 in our institution		>1000 copies/mLProgressive disease and severe illness despite treatment for COVID-19.
Admission to ICU and IMV may be required.		Similar to COVID-19
Grand-glass opacity Lobar or segmental infiltrates
Cysts, nodules, effusion data
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Gioia, F.; Albasata, H.; Hosseini-Moghaddam, S.M. Concurrent Infection with SARS-CoV-2 and Pneumocystis jirovecii in Immunocompromised and Immunocompetent Individuals. J. Fungi 2022, 8, 585. https://doi.org/10.3390/jof8060585

AMA Style

Gioia F, Albasata H, Hosseini-Moghaddam SM. Concurrent Infection with SARS-CoV-2 and Pneumocystis jirovecii in Immunocompromised and Immunocompetent Individuals. Journal of Fungi. 2022; 8(6):585. https://doi.org/10.3390/jof8060585

Chicago/Turabian Style

Gioia, Francesca, Hanan Albasata, and Seyed M. Hosseini-Moghaddam. 2022. "Concurrent Infection with SARS-CoV-2 and Pneumocystis jirovecii in Immunocompromised and Immunocompetent Individuals" Journal of Fungi 8, no. 6: 585. https://doi.org/10.3390/jof8060585

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop